Shares in Value Logo
Product Review Img Vertical

Date : 12/03/2021

ResApp (ASX:RAP) shares up by over 15%. Learn why.

ResApp Health (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory diseases. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved, and clinically validated products include – ResAppDx, a smartphone-based acute respiratory disease diagnostic test that is used in telehealth, emergency departments and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnea. Both products are CE Marked in Europe and TGA approved in Australia.

ResApp shares recovered very quickly from the lows of the pandemic. However, the stock has gradually kept falling and ResApp shares have returned -37% in the past 6 months.

Today, ResApp announced that it has won a licensing deal from AstraZeneca’s Japanese subsidiary for its cough counting technology. Under the terms of the agreement, ResApp’s cough counting technology will be integrated into the asthma management smartphone app that is developed by AstraZeneca. This is being used to assist patients in monitoring symptoms right from their homes.

AstraZeneca will be paying ResApp an annual licence fee for each patient that utilises the service and it is the first time that ResApp’s technology is being used outside of a clinical trial setting. ResApp is by no means a top healthcare stock on the ASX just yet, but this announcement is definitely a step in the right direction.

Looking for Growth Stocks?

Growth stocks are potentially one of the hardest to pick as there are a lot of factors that need to be considered – from industry tailwinds to financial health of the individual stocks, and a lot of little things in between them. Shares in Value research team have picked their top 3 ASX stocks to buy in 2021. Click here to download the report for free.


Are You Looking To Buy The Best Stocks In 2024?

Stay on top of upcoming market trends! Whether you are an SMSF investor or a young investor with your portfolio, we cover a wide range of stocks across all sectors, including mining, financials, industrials, real estate, technology, health and biotech, etc. It will give you an edge to invest and trade ASX listed stocks across large, mid and small caps with an advantage.

Get stock tips with our Market Experts. We help self-directed investors and self-managed super funds (SMSF) make smarter investment decisions and get better returns. Fill in your details and download your free Report instantly for Top 3 Dividend Stocks to buy in 2024!


Top 5 ASX Stocks
to Buy for Capital Growth in 2024

Shares In Value - Top 5 ASX Stocks to Buy - Cover 2024
The hardest part to finding growth stocks is having an ability to understand the finer details of these companies from their valuations through to first mover advantage and having key factors on hand to make informed investment decisions.

Our experts take the guesswork out.
ASX insight Stocks Landing

Download Your Free Report

By downloading this report, you agree to our terms and conditions and privacy policy

Scroll to Top


By submitting this form, I agree to the TERMS AND CONDITIONS and PRIVATE POLICY

Income Stocks - Blogs

Please fill in your details to download the free dividend shares report.

By downloading this report, you agree to our terms and conditions and privacy policy

Just 10 Seconds Away From Your Free Report!
Income Stocks - Popup Blog

Please fill in your details to download the free dividend shares report.

By clicking 'Download Report', I accept the Privacy Policy and Member Terms & Conditions.

We will send your report instantly. Please put your correct email address and phone number.